Complex Critical Illness (ARDS) Flashcards

1
Q

ARDS

A

complex syndrome characterized by:

1) non-cardiogenic pulmonary edema
2) severe hypoxemia (often resistant to O2 therapy)
3) characteristic CXR changes
4) decreased lung compliance

arises from direct insult (e.g. pneumonia) or indirect insults (e.g. pancreatitis, sepsis).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ARDS happens when…

A

out of control inflammatory response occurs in the lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

a normal alveolar-capillary has…

A

a dry alveolus and perfused capillary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the three phases of ARDS?

A

exudative, proliferative, fibrotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

exudative phase

A
  • begins 24hrs after insult

1) injury/insult to either capillary or alveolus

2) chemical mediators of inflmtn = injury to pulm capillaries = inc a/c membrane permeability = leakage of fluid filled with protein, blood, cells, fibrin to interstitial space + formation of microthrombi

3) pulm edema begins
- type 1 cells die
- compression of alveoli and small airways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

clinical presentation in exudative phase

A
  • restless, dyspnea, tachypnea
  • coarse crackles
  • mech vent needed
  • CXR with patchy infiltrates
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

proliferative phase

A
  • type 2 alveolar cells destroyed
  • decreased surfactant production
  • alveolar cells start to collapse
  • oxygenation severely impaired
  • CO2 removal continues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

clinical presentation after proliferative phase

A
  • SIRS fully manifested
  • HI
  • generalized edema
  • worsening hypoxemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

fibrotic phase

A
  • alveoli become enlarged and irregularly shaped (fibrotic)
  • pulm capillaries become scarred
  • continued stiffening of lungs inc pulm HTN
  • continued hypoxemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

clinical presentation after fibrotic phase

A

MODS
refractory hypoxemia
increasing PaCO2
risk of pneumothorax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what would interstitial edema do to the O2 S+D?

A

thickened AC membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what would pulm edema do to the O2 S+D?

A

shunt/shunt like units
decreased SA
decreased compliance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what would alveolar compression/collapse do to the O2 S+D?

A

decreased SA
increased a/w
decreased FRC
decreased compliance
decreased volumes
increased demand (WOB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what would loss of surfactant do to the O2 S+D?

A

decreased compliance
decreased volumes
increased demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what would capillary damage and microemboli do to the O2 S+D?

A

dead space like
increased RV afterload
worsening PA pressures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what would progressive fibrosis and protein layer do to the O2 S+D?

A

thickened AC membrane
decreased compliance
decreased volumes
increased demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ARDS pathology summary

A
  • injury to lungs
  • inflammatory process triggered
  • chemical mediators released systemically and locally
  • increased capillary permeability occurs
  • fluid shifts across a-c membrane into interstitial space
  • fluid and proteins into alveolar space = pulm edema
  • V/Q mismatch of shunt and hypoxemia
  • decreased diffusion, loss of SA, thickened AC membrane, and more hypoxemia
  • decreased surfactant production and alveolar injury = decreased compliance and ventilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ARDS resolution - fibroproliferative

A
  • resolution of pulm edema
  • protein based layer cleared
  • type 2 cells multiply
  • structural and vascular remodelling occurs
  • damaged type 1 and 2 cells may be replaced by collagen/scar tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

fibrotic alveoli affects the O2 supply and demand how?

A

decreased compliance
increased AC membrane thickness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

fibrotic capillaries cause?

A

increased PVR/PAD
pulm HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

ARDS Dx: Berlin Criteria

A

1) timing
2) chest imaging
3) origin of edema
4) oxygenation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

berlin criteria: timing

A

within 1 week of known clinical insult or new/worsening resp symptoms (most ARDS pts identify within 72hrs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

berlin criteria: chest imaging

A

bilateral opacities, not fully explained by effusions, lobar/lung collapse, or nodules (white out, change may not be evident for 24hrs)

24
Q

berlin criteria: origin of edema

A

resp failure not fully explained by cardiac failure or fluid overload. need to exclude hydrostatic edema if no risk factor present.

25
cardiogenic edema would show...
S3, new or changed murmur, elevated JVD, cardiomegaly, elevated BNP, poor EF, aortic or mitral valve dysfunction, severe diastolic dysfunction
26
PCWP and SVR are _____ in cardiogenic shock
decreased
27
PAD is influenced by
blood flow, pulmonary vascular tone
28
how are PCWP and PAD values in heart failure vs ARDS?
PCWP is closer to PAD
29
in ARDS, pulm edema must be....
non-cardiogenic in nature
30
oxygenation (with PEEP >=5): PaO2 - FiO2
mild = 200-300mmHg % of shunting = 5-15% moderate = 100-200 % of shunting = 15-20% severe = <=100mmHg % of shunting = >20%
31
PaO2 FiO2 ratio calculation
PaO2/FiO2 ex. 100/0.21
32
ARDS management
1) Treat cause 2) support framework (protective lung strategies, optimize gas exchange, fluid therapy, pharmacology)
33
protective lung strategies
- low TV 4-8cc/kg IBW to prevent volutrauma and regional overdistention - plateau pressure <30cm H20 - permissive hypercapnia
34
PIP/pPeak is monitored in...
controlled modes of ventilation
35
PIP is influenced by
TV, compliance, airway resistance, ventilator circuit resistance
36
increasing PIP over time can indicate that...
lung compliance is decreasing
37
plateau pressure
- measured at end of inspiration - more reflective of compliance than PIP - <30cm H2O = goal to prevent volutrauma and barotrauma
38
pressure control ventilation
- used in dec lung compliance pts - minimize risk of baro/volutrauma - control amount of pressure - provides controlled and assisted breaths
39
what do we set for ventilation on PC?
- pressure: inspiratory pressure level (15-25cm H2O) - RR/f - inspiratory time - trigger sensitivity for pt initiated breaths
40
what do we set for oxygenation on PC?
PEEP, FiO2
41
what parameters will fluctuate on PC?
- RR/f - TV/mV - etCO2
42
pPeak = _____ + ______
PEEP + PC ex. PEEP 5, PC = 20, therefore pPeak = 25
43
what flow does PC produce?
laminar flow - opens smaller airways and alveoli, helping with recruitment
44
permissive hypercapnia
- allowing CO2 to rise - decreases risk of volu/braotrauma and auto PEEP - new goal is pH >7.20 - not used in pts with seizures or high ICP
45
optimize gas exchange/ventilation
- PEEP recruit alveoli and prevent collapse - suction when necessary to reduce shunt-like airway - optimize CO to reduce dead space - positioning - good lung down, prone
46
prone positioning
- reduces pressure of organs on lungs to allow for more alveoli expansion - fluid drains downwards reducing pressure - posterior lungs have more blood vessels - risks = skin breakdown, facial/ocular edema, tube dislodging, ++ staff
47
refractory hypoxemia
accepting a lower SaO2 target
48
fluid therapy
key is to optimize preload without worsening pulm edema
49
biphasic fluid management
- 1st treat initial HI caused by SIRS to optimize CO - then restrictive fluid management - give fluid carefully
50
pharmacology
1. decrease O2 demand 2. tolerance of vent 3. bronchodilators 4. pulmonary vasodilators 1&2 = fever control, analgesics, sedatives, NMBS
51
pulmonary focused drugs
- bronchodilators for a/w patency - surfactant replacement drugs - NO and flolan
52
nitric oxide (NO)
- acts on endothelium creating vasodilation of capillary bed without systemic vasodilation - reduces PVR, improves blood flow, and reduces V/Q mismatch - improves gas exchange by enhancing blood flow to ventilated areas of lungs
53
side effect of NO
interacts with Hgb to form methohemoglobin, which impairs release of O2 at the cellular level
54
flolan - epoprostenol
- IV vasodilator (or aerosol connected to a vent) - increases pulmonary arterial flow and decreases pulmonary pressures = improved gas exchange and arterial oxygenation
55
2 major pharmacological actions of flolan
1) direct vasodilation of pulmonary and systemic arterial vascular beds 2) inhibition of platelet aggregation
56
nursing implications for flolan
- IV has short (3 min) half life - can cause bleeding - sudden withdrawal of drug can cause rebound pulmonary hypertension - stable for 8 hrs in room temp, otherwise needs ice packs
57
pulmonary vasodilators are...
- managed by the RT - inhaled through the ventilator - should see results w/in mins (increased SpO2 and decreased PA pressures) - must wean off, otherwise rebound effect of pulmonary HTN - need to bag patient? Bag with O2/Nitric/Flolan mix